Trial Profile
Add-on, open-label, phase III study of CS-866AZ
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/azelnidipine (Primary)
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 20 May 2016 New trial record